Bullish & Foolish
Full MNPR fundamentals All 466 on the Survival Watch

MNPRMonopar Therapeutics Inc.

Is Monopar Therapeutics struggling financially?

Yes, by its own account. Monopar Therapeutics told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$723.0M
Source filing
10-Q 14 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 24months

    If the burn speeds up

    Empty by Jun 2028

  • 33months

    If it eases off

    Empty by Mar 2029

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$52.8M

÷

Cash burned over the last 12 months

$22.4M

What Monopar Therapeutics told the SEC

…the date on which the financial statements are available to be issued, when applicable). Further, a company must provide certain disclosures if there is “substantial doubt about the entity’s ability to continue as a going concern.” In March 2026, the Company analyzed its cash requirements through December 31, 2027, and has determined that, based upon the Company’s current available cash and cash equivalents,…

Monopar Therapeutics Inc., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 22.1% share-count increase The company issued stock. Each share now owns 18.1% less of the business than a year ago, before any change in the price.
  • Cash burn is increasing It is spending 19% more cash per year than it was, so the runway above shortens even if nothing else changes.

Other Biotech/Pharma companies that filed the doubt